cas 916420-27-4|| where to buy tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

Nombre del producto:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

IUPAC Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

Unidad de embalaje	Stock disponible	Precio($)
CM104183-5g	in stock	ȋƩ
CM104183-10g	in stock	ƏŭƏ
CM104183-25g	in stock	ƅǺƅ
CM104183-100g	in stock	Ȥşœ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 916420-27-4 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :916420-27-4; Fórmula molecular:C12H15Cl2N3O2; Punto de fusión:-; Código de sonrisas:CC(C)(C)OC(=O)N1CCC2=C(Cl)N=C(Cl)N=C2C1; Densidad:

: Número de catálogo:CM104183; Peso molecular:304.17; Punto de ebullición:; Nº Mdl:MFCD09025732; Almacenamiento:

: Adagrasib; Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.